A5075906241- Chronic Lymphocytic Leukemia Research
- Lymphoma Diagnosis and Treatment
- Acute Lymphoblastic Leukemia research
- Childhood Cancer Survivors' Quality of Life
- Monoclonal and Polyclonal Antibodies Research
- Immunodeficiency and Autoimmune Disorders
- Immune Cell Function and Interaction
- Chronic Myeloid Leukemia Treatments
- Phagocytosis and Immune Regulation
- Acute Myeloid Leukemia Research
- CAR-T cell therapy research
- Amyloidosis: Diagnosis, Treatment, Outcomes
- Glycosylation and Glycoproteins Research
- Cancer survivorship and care
- Myeloproliferative Neoplasms: Diagnosis and Treatment
- Cancer Immunotherapy and Biomarkers
- Vitamin C and Antioxidants Research
- Histone Deacetylase Inhibitors Research
- CNS Lymphoma Diagnosis and Treatment
- Pharmaceutical studies and practices
- Nutrition and Health in Aging
- Chemotherapy-induced cardiotoxicity and mitigation
- Hemophilia Treatment and Research
- Hematological disorders and diagnostics
- Neutropenia and Cancer Infections
The University of Queensland
2015-2024
Princess Alexandra Hospital
2015-2024
Queensland Health
2024
Australasian Leukaemia and Lymphoma Group
2023
Queensland University of Technology
2021
Translational Research Institute
2020-2021
Princess Alexandra Hospital
2017-2019
University Medical Center Utrecht
2019
Canberra Hospital
2006
First reported in 1999, germline runt-related transcription factor 1 (RUNX1) mutations are a well-established cause of familial platelet disorder with predisposition to myeloid malignancy (FPD-MM). We present the clinical phenotypes and genetic detected 10 novel RUNX1-mutated FPD-MM families. Genomic analyses on these families 2 partial gene deletions, 3 mutations, 5 recurrent as RUNX1 alterations leading FPD-MM. Combining genomic data from herein aggregated published sets resulted 130...
Febrile neutropenia (FN) is a medical emergency and can represent life-threatening complication for hematology patients treated with intensive chemotherapy regimens. In clinical practice, the diagnostic yield of blood cultures other investigations which aim to identify causative organism or site infection low. We have retrospectively examined all collected in "real world" cohort receiving acute leukemia aggressive lymphoma Hyper-CVAD/MTX-cytarabine, at single tertiary center over five-year...
The first patient was a 66-year-old man with brain only metastasis. He had background of β thalassaemia trait, baseline haemoglobin (Hb) concentration 115 g/l and mean corpuscular volume (MCV) 62 fl. After 1 month therapy his Hb decreased to 80 g/l. Haemolytic markers were abnormal, including unconjugated bilirubin 31 μmol/l, lactate dehydrogenase (LDH) 758 units/l, haptoglobin 0.04 reticulocyte count 140 × 109/l. A direct anti-globulin test (DAT) negative. His blood film (left) showed...
Pediatric regimens have improved outcomes in adolescent and young adult (AYA) acute lymphoblastic leukemia (ALL). However, results remain inferior to children with ALL. The Australasian Leukaemia Lymphoma Group (ALLG) ALL06 study (anzctr.org.au/ACTRN12611000814976) was designed assess whether a pediatric ALL regimen (Australian New Zealand Children's Haematology Oncology [ANZCHOG] Study 8) could be administered patients aged 15 39 years comparable time frame as assessed by the proportion of...
Please note: The publisher is not responsible for the content or functionality of any supporting information supplied by authors. Any queries (other than missing content) should be directed to corresponding author article.
Chronic lymphocytic leukemia (CLL) is the most common adult leukemia. While therapeutic antibodies show clinical activity in CLL patients, resistance inevitably develops resulting treatment failure. Identifying mechanisms of antibody and methods to reduce would be valuable managing CLL. Monocyte derived cells (MDCs), also known as nurse like (NLCs) [1], [2], are crucial components microenvironment network following "maturation" vitro culture systems able provide support for survival...
<p>Supplement</p>
<div>AbstractPurpose:<p>Marginal zone lymphoma (MZL) is an uncommon non–Hodgkin with malignant cells that exhibit a consistent dependency on B-cell receptor signaling. We evaluated the efficacy and safety of zanubrutinib, next-generation selective Bruton tyrosine kinase inhibitor, in patients relapsed/refractory (R/R) MZL.</p>Patients Methods:<p>Patients R/R MZL were enrolled phase II MAGNOLIA (BGB-3111–214) study. The primary endpoint was overall response rate (ORR)...
Hodgkin’s lymphoma (HL)-associated vanishing bile duct syndrome (VBDS) is a paraneoplastic phenomenon leading to cholestasis, end-stage liver failure and potentially death, due cholestatic dysfunction typically precluding the commencement of curative intent chemotherapy. A female in her 20s presented with pruritus, jaundice hepatitis on laboratory tests, confirmed as VBDS biopsy. CT chest demonstrated mediastinal mass widespread cervical lymphadenopathy. The patient received 30.6 Gy 17...
Antibody therapies are important treatment options for Chronic lymphocytic leukemia (CLL). Monocyte-derived-macrophages (MDMs) thought to be a major immune effector that clears leukaemic cells ...